Prophylactic alternative to aspirin in patients w/ atherosclerosis who are at risk of thromboembolic disorders (eg, MI, peripheral arterial disease & stroke). In combination w/ aspirin: Acute coronary syndromes including acute MI, unstable angina & coronary stenting; adjunct in the management of acute ST-elevation MI, unstable angina & non-Q-wave MI.
Prophylaxis of thromboembolic events 75 mg once daily. Management of acute ST-elevation MI 75 mg once daily. Patient <75 yr May give loading dose 300 mg. Continue treatment for at least 4 wk. Management of unstable angina & non-Q-wave MI Single loading dose: 300 mg; followed by 75 mg once daily.
Do not administer in patients w/ hematopoietic disorder eg, neutropenia or thrombocytopenia, haemorrhagic diathesis or other haemorrhagic disorders associated w/ prolonged bleeding time; conditions w/ increased risk of bleeding eg, GI ulcer, acute cerebral haemorrhage or severe liver dysfunction. Monitor blood counts w/in 2 wk of stopping treatment. Discontinue therapy 10-14 days pre-op.
Increased risk of bleeding w/ anticoagulants & antiplatelets. May inhibit the metabolism of other drugs metabolized in the liver. Reduced clearance w/ cimetidine. Antagonize effect on bleeding time w/ corticosteroids.
Sign Out
